Biotech Values

[genisi]

In general, I don't think anyone expects biosimilars to behave like conventional oral solid dose generics and capture 90% of the market quickly following launch. A key question imo is - how willing clinicians and payers are to use a cheaper biosimilar. This is influenced by many issues: type of treatment market, critical care or chronic, dosing (like with Avonex vs. Rebif), device of administration (as with GH biosimilars which have only made a smallish impact - less than 5% of market share), meaningful clinical or label differentiation to the brands (recall that even with no such differences Dynepo was a failure).